After more than 30 years of a one-size-fits-all approach in the management of advanced ovarian cancer, in 2018 the SOLO1 trial results have introduced a new era of personalized medicine. A deeper knowledge of ovarian cancer biology and the development of new drugs targeting specific molecular pathways have led to biomarker-driven phase 3 trials with practice changing results. Thereafter, platinum-based combinations are no longer the only therapeutic options available in first line setting and poly-ADP ribose polymerase inhibitors maintenance therapy has become the mainstay in patients with tumor harboring a homologous recombination defect. However, most of the recent therapeutic breakthroughs regard high grade serous carcinoma, the most frequent ovarian cancer subtype, and only few improvements have occurred in the management of less common histotypes. Moving towards the next challenges, we aimed to investigate and review new potential molecular targets in ovarian cancer, according to histotype, starting from promising molecular drivers and matched drugs that have been investigated in early and late-stage clinical trials or conceptualized in preclinical studies.

Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors

Tuninetti V.;Valabrega G.;
2021-01-01

Abstract

After more than 30 years of a one-size-fits-all approach in the management of advanced ovarian cancer, in 2018 the SOLO1 trial results have introduced a new era of personalized medicine. A deeper knowledge of ovarian cancer biology and the development of new drugs targeting specific molecular pathways have led to biomarker-driven phase 3 trials with practice changing results. Thereafter, platinum-based combinations are no longer the only therapeutic options available in first line setting and poly-ADP ribose polymerase inhibitors maintenance therapy has become the mainstay in patients with tumor harboring a homologous recombination defect. However, most of the recent therapeutic breakthroughs regard high grade serous carcinoma, the most frequent ovarian cancer subtype, and only few improvements have occurred in the management of less common histotypes. Moving towards the next challenges, we aimed to investigate and review new potential molecular targets in ovarian cancer, according to histotype, starting from promising molecular drivers and matched drugs that have been investigated in early and late-stage clinical trials or conceptualized in preclinical studies.
2021
Dec 101
102298
102305
Druggable alterations; Ovarian cancer; PARP inhibitors; Precision medicine; Target therapy; Treatment tailoring; Antineoplastic Agents; Drug Development; Female; Humans; Neoplasm Staging; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Molecular Targeted Therapy; Ovarian Neoplasms
Bartoletti M.; Musacchio L.; Giannone G.; Tuninetti V.; Bergamini A.; Scambia G.; Lorusso D.; Valabrega G.; Mangili G.; Puglisi F.; Pignata S.
File in questo prodotto:
File Dimensione Formato  
Bartoletti et al _2021.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 961.17 kB
Formato Adobe PDF
961.17 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1844904
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact